黑料网

An innovative inhibitor that shows promise for combating obesity and possibly preventing heart disease has been successfully developed by a multidisciplinary research team at The University of Texas at San Antonio. Researcher leading in the development of an anti-obesity medication that inhibits the activity of the enzyme cytochrome P450 8B1, which is linked to cholesterol absorption and obesity [1].

Scholar sent test samples to Chung's laboratory, which is funded by the National Institutes of Health. There, she and her team are studying the effects of bioactive compounds, which are chemicals found in small amounts in plants and some foods, and how exercise can be used to treat obesity and other metabolic disorders [2].

Description

As a child, I had the aspiration of assisting members of my family who suffered from obesity, heart disease, and other medical conditions. We have developed a small molecule that can be used to combat obesity, a problem that affects many families worldwide [3], and this dream is now becoming a reality.

As an exercise physiologist, I truly believe that physical activity is the most effective treatment for noncommunicable diseases. Unfortunately, very few people exercise regularly, and the rate of obesity is steadily rising. I have high hopes for additional testing based on promising data.

The drug developed by UTSA has the potential to halt the enzyme P450 8B1, which is responsible for the body's production of cholic acid. In turn, this inhibition slows down the absorption of cholesterol. This procedure may hold the key to treating metabolic disorders caused by obesity as well as other obesity-related diseases like diabetes and heart disease.

The team conducted research that included giving the inhibitor drug to mice for seven days. Despite eating a high-fat, high-sugar diet, the result was a drop in the amount of glucose in their blood without affecting their weight. The outcomes show the way that a P450 8B1 inhibitor could prompt a better metabolic profile and its true capacity could prompt fostering a remedial technique to treat heftiness related insulin obstruction [4].

Conclusions

The work of the researchers exemplifies the goal of UTSA, which is to come up with solutions for difficult problems that will boost society's health and well-being. A drug that works to prevent obesity could improve people's quality of life all over the world.

In 2016, the World Health Organization estimated that 1.9 billion adults worldwide were overweight and 650 million were obese. In the United States, heart disease accounts for one in every four deaths, and obesity is a major cause. According to a recent report from the San Antonio Metropolitan Health District [5], 71% of adults in the area are overweight or obese.

By treating obesity and heart disease, our synthetic chemistry research can significantly improve society's well-being, as demonstrated by these outcomes.

Acknowledgement

None

Conflict of Interest

None

1. Bibbins-Domingo K, Coxson P, Pletcher MJ, Lightwood J, Goldman L (2007) . N Engl J Med 357: 2371-2379.

, ,

2. Eckel RH, Krauss RM (1998) . Circulation 97: 2099-2100.

, ,

3. Curtis JP, Selter JG, Wang Y, Rathore SS, Jovin IS, et al. (2005) . Arch Intern Med 165: 55-61.

, ,

4. Guo F, Moellering DR, Garvey WT (2014) . Obesity 22: 110-118.

, ,

5. Van de Voorde J, Pauwels B, Boydens C, Decaluwé K (2013) . Metabolism, 62: 1513-1521.

, ,